127 related articles for article (PubMed ID: 38153423)
1. The ability and optimal cutoff value of serum cell division cycle 42 in estimating major adverse cardiac event in STEMI patients treated with percutaneous coronary intervention.
Luan S; Zhang L; Cheng X; Wang Y; Feng Q; Wei L; Jiang F; Liu J
Heart Vessels; 2024 Apr; 39(4):277-287. PubMed ID: 38153423
[TBL] [Abstract][Full Text] [Related]
2. Serum histone deacetylase 4 longitudinal change for estimating major adverse cardiovascular events in acute coronary syndrome patients receiving percutaneous coronary intervention.
Xu H; Zhang J; Jia H; Xing F; Cong H
Ir J Med Sci; 2023 Dec; 192(6):2689-2696. PubMed ID: 36849652
[TBL] [Abstract][Full Text] [Related]
3. Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients.
Yu J; Liu Y; Peng W; Xu Z
J Clin Lab Anal; 2022 Oct; 36(10):e24685. PubMed ID: 36045604
[TBL] [Abstract][Full Text] [Related]
4. The abnormal level and prognostic potency of multiple inflammatory cytokines in PCI-treated STEMI patients.
Zhang J; Xu H; Yao M; Jia H; Cong H
J Clin Lab Anal; 2022 Nov; 36(11):e24730. PubMed ID: 36245413
[TBL] [Abstract][Full Text] [Related]
5. Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.
Perera D; Crake T; Lee V
Crit Pathw Cardiol; 2018 Jun; 17(2):77-82. PubMed ID: 29768315
[TBL] [Abstract][Full Text] [Related]
6. In-hospital major adverse cardiovascular events after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: a retrospective study under the China chest pain center (standard center) treatment system.
Huang L; Zhang J; Huang Q; Cui R; Chen J
BMC Cardiovasc Disord; 2023 Apr; 23(1):198. PubMed ID: 37069503
[TBL] [Abstract][Full Text] [Related]
7. The clinical utility of circulating cell division control 42 in small-vessel coronary artery disease patients undergoing drug-coated balloon treatment.
Wu L; Li H; Chen H; Fan C; Lu Y; Wei R; Yang G; Jia Y
BMC Cardiovasc Disord; 2023 Oct; 23(1):496. PubMed ID: 37805479
[TBL] [Abstract][Full Text] [Related]
8. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Yang L; Dong H; Lu H; Liao Y; Zhang H; Xu L; Tan Y; Cao S; Tan J; Fu S
Medicine (Baltimore); 2019 Mar; 98(12):e14920. PubMed ID: 30896649
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of platelet/lymphocyte ratio and CAMI-STEMI score for major adverse cardiac events in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: A prospective observational study.
Wang Y; Peng Z
Medicine (Baltimore); 2021 Aug; 100(33):e26942. PubMed ID: 34414954
[TBL] [Abstract][Full Text] [Related]
10. One-year Outcomes in Patients with ST-segment Elevation Myocardial Infarction Caused by Unprotected Left Main Coronary Artery Occlusion Treated by Primary Percutaneous Coronary Intervention.
Liu HW; Han YL; Jin QM; Wang XZ; Ma YY; Wang G; Wang B; Xu K; Li Y; Chen SL
Chin Med J (Engl); 2018 Jun; 131(12):1412-1419. PubMed ID: 29893357
[TBL] [Abstract][Full Text] [Related]
11. Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study.
Chen Y; Jiang D; Tao H; Ge P; Duan Q
BMC Cardiovasc Disord; 2022 Oct; 22(1):434. PubMed ID: 36199038
[TBL] [Abstract][Full Text] [Related]
12. Predictive values of bilirubin for in-hospital adverse events in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.
Ying C; Liu CF; Guo DQ; Du ZR; Wei YJ
Clinics (Sao Paulo); 2023; 78():100306. PubMed ID: 37949037
[TBL] [Abstract][Full Text] [Related]
13. Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention.
Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Catheter Cardiovasc Interv; 2020 Feb; 95(2):E40-E55. PubMed ID: 31423723
[TBL] [Abstract][Full Text] [Related]
14. Impact of infarct location and size on clinical outcome after ST-elevation myocardial infarction treated by primary percutaneous coronary intervention.
Reindl M; Holzknecht M; Tiller C; Lechner I; Schiestl M; Simma F; Pamminger M; Henninger B; Mayr A; Klug G; Bauer A; Metzler B; Reinstadler SJ
Int J Cardiol; 2020 Feb; 301():14-20. PubMed ID: 31761400
[TBL] [Abstract][Full Text] [Related]
15. Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention.
Liu HT; Chen M; Yu J; Li WJ; Tao L; Li Y; Guo WY; Wang HC
Medicine (Baltimore); 2015 Jan; 94(4):e449. PubMed ID: 25634182
[TBL] [Abstract][Full Text] [Related]
16. Sex-Related Differences in Short- and Long-Term Outcome among Young and Middle-Aged Patients for ST-Segment Elevation Myocardial Infarction Underwent Percutaneous Coronary Intervention.
Fu WX; Zhou TN; Wang XZ; Zhang L; Jing QM; Han YL
Chin Med J (Engl); 2018 Jun; 131(12):1420-1429. PubMed ID: 29893358
[TBL] [Abstract][Full Text] [Related]
17. Serum ACSL4 levels in patients with ST-segment elevation myocardial infarction (STEMI) and its association with one-year major adverse cardiovascular events (MACE): A prospective cohort study.
Hu Y; Li Q; Wang Y
Medicine (Baltimore); 2024 Jan; 103(2):e36870. PubMed ID: 38215103
[TBL] [Abstract][Full Text] [Related]
18. A risk score based on simple angiographic characteristics to aid in choosing the optimal revascularization strategy for patients with multivessel disease presenting with ST-elevation myocardial infarction.
Schamroth Pravda N; Witberg G; Zusman O; Landes U; Bental T; Assali A; Vaknin Assa H; Greenberg G; Codner P; Perl L; Kornowski R
Coron Artery Dis; 2020 Nov; 31(7):597-605. PubMed ID: 32271245
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of fractalkine/CX3CL1 concentration in patients with acute myocardial infarction treated with primary percutaneous coronary intervention.
Xu B; Qian Y; Zhao Y; Fang Z; Tang K; Zhou N; Li D; Wang J
Cytokine; 2019 Jan; 113():365-370. PubMed ID: 30352758
[TBL] [Abstract][Full Text] [Related]
20. Immediate complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease treated by primary percutaneous coronary intervention: Insights from the ORBI registry.
Pimor A; Auffret V; Didier R; Delaunay R; Filippi E; Hacot JP; Saouli D; Rouault G; Druelles P; Bot E; Coudert I; Boulanger B; Le Guellec M; Boulmier D; Leurent G; Bedossa M; Gilard M; Le Breton H
Arch Cardiovasc Dis; 2018 Nov; 111(11):656-665. PubMed ID: 29229216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
